Device Trial Radar · NCT04245527
Use of Infrared Photomodulation for Hormonal Balance (Joovvin' for Hormonal Health)
Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jan 31, 2020
Primary completion
May 1, 2020
Study completion Jun 1, 2020
Sponsor
- Lead sponsor
- ProofPilotNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Joovv
- First posted
- Jan 29, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
8-week pilot study looking at the impact of Joovv's infrared photo modulation product on male and female hormone levels.
Conditions
- Testosterone Deficiency
- Estrogen Deficiency
Interventions
Joovv Infrared Light DeviceDevice
Joovv is the leading manufacturer of personal, in-home red light therapy devices
Primary outcomes
What the sponsor says the trial is designed to measure.
- Testosterone ChangeTime frame: baseline to week 8
- change of thyroid-stimulating hormone (TSH)Time frame: baseline to week 8
- Self report general wellnessTime frame: baseline to week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ProofPilot (Virtual Study: https://p.proofpilot.com)
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.